Transaction in Own Shares – Correction

Transaction in Own Shares - Correction October 23, 2013 - This announcement replaces Shire's announcement releasedtoday under Number 32206-BAF7. The number of Ordinary Shares held as treasury shares and the number ofOrdinary Shares in issue (excluding treasury shares) were incorrectly stated.All other details remain unchanged. The full amended text is shown below. October 23, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announcesthat, in accordance with the authority granted by shareholders at the Company'sAnnual General Meeting on April 30, 2013, it purchased 5,998 of its ordinaryshares of 5 pence each ("Ordinary Shares") on October 22, 2013 through bothdirect purchases of Ordinary Shares, and through the purchase of OrdinaryShares underlying ADRs. The highest and lowest price paid for the directlyacquired Ordinary Shares was 2515.00 pence per share and 2491.00 pence pershare respectively, and for those Ordinary Shares acquired though the purchaseof ADRs was 4073.67 cents per share and 4054.67 cents per share respectively. The purchased shares will be held as treasury shares. Following the abovepurchase, the Company holds 9,807,835 Ordinary Shares as treasury shares andhas 553,137,062 Ordinary Shares in issue (excluding treasury shares). The purchases were made by an independent third party which makes its tradingdecisions independently of, and uninfluenced by, the Company. The independenceof the third party enables the Company to continue to purchase Ordinary Shares(including Ordinary Shares underlying ADRs) during close periods and otherprohibited periods, should they arise. The third party has been appointed bythe Company to make purchases to December 31, 2013. For further information please contact: Investor Relations Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,Internal Medicine and Regenerative Medicine and we are developing treatmentsfor symptomatic conditions treated by specialist physicians in other targetedtherapeutic areas. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX Press Release www.shire.com